Definitive Contract HHSN261201000134C
Award Date 9/30/10
Potential Completion Date 6/29/11
Potential Value $200K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Roxbury, MA 02118, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
11
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $199,892.00 federal contract awarded by the National Cancer Institute, a civilian agency, to Eutropics Pharmaceuticals, a for-profit small business. The contract is for basic research and development in the "OTHER FUNCTIONS R & D- BIOMEDICAL (BASIC RESEARCH)" domain as part of the SBIR Program Phase I. The contract is a definitive, firm fixed-price agreement with a completion date of June 21, 2013. This contract award has a total small business set-aside designation.
- This is a $1,498,266.01 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute, a civilian agency, to Eutropics Pharmaceuticals for the development of BH3 profiling as a companion diagnostic for Velcade treatment of multiple myeloma. The contract has a total small business set-aside designation and an ultimate completion date of March 2, 2016. This award appears to be part of the National Cancer Institute's broader efforts to support the development of diagnostics and...
- <p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Santech, Inc., a small business. The contract, with a ceiling value of $954,958, is for a Small Business Innovation Research (SBIR) Program Phase II action. The contract is a definitive contract with a cost plus fixed fee pricing type, and the ultimate completion date is March 23, 2014. The contract has a total small business set-aside designation.</p>
- <p>This is a $299,356.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Entropia Biosciences Inc., a self-certified small disadvantaged business. The contract is for research and development in the biomedical field, specifically for a SBIR Program Phase I action. The contract has a set-aside designation for total small business. The award date was September 22, 2015, and the ultimate completion date is June 21, 2016.</p>
- <p>This is a $299,990.00 firm-fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Evorx Technologies, Inc., a small disadvantaged business. The contract was set aside for small businesses. The award is for an unspecified product or service related to the NCI's mission, with a period of performance ending on February 28, 2017. No additional details about the specific requirements or work to be performed are provided.</p>
- This is a federal contract award to Biotex, Inc., a for-profit organization and manufacturer of goods, by the National Cancer Institute (NCI), a civilian agency. The contract is for the "Development of Alternative Affinity Capture Reagents for Cancer Proteomics Research" under the Small Business Innovation Research (SBIR) Phase II program, with a total ceiling value of $749,995.92. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type and has an ultimate...
- This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pharmaco-Kinesis Corporation, a small business, for a Phase I project entitled "A VEGF Nanosensor to Monitor Tumor Progression". The contract has a ceiling value of $170,009.00 and an ultimate completion date of August 27, 2013. The contract was awarded on September 28, 2012 under the "Other Functions Topic 301" solicitation. No additional details about subcontractors...
- <p>This is a $149,499.00 firm fixed-price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to L-Nutra, Inc., a for-profit small business organization. The contract is for "Medicinal Food for the Protection of Patients and Sensitization of Cancer Cells to Chemotherapy." It has a period of performance ending on April 7, 2011. The contract was awarded on September 30, 2010 and is set aside for small businesses.</p>
- This federal contract was awarded by the National Cancer Institute, a civilian agency, to Micro TECH International Inc., a self-certified small disadvantaged business. The firm fixed price contract is a BPA (Blanket Purchase Agreement) call with a ceiling value of $10,687.42 and a completion date of December 31, 2015. The contract does not have a set-aside designation. The award is not associated with a larger contract vehicle, and no other subcontractors are specified. The contract's purpose is...
- <p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Biotex, Inc. The contract is for the development of glycosylation-specific research, with a ceiling value of $149,919.00 and a completion date of October 14, 2012. The contract is a definitive contract with a firm fixed-price pricing type. This SBIR Phase I action is a set-aside for small businesses.</p>